Free from Publisher

Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells

SV Bachawal, VB Wali, PW Sylvester - Anticancer research, 2010 - ar.iiarjournals.org
Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …
被引用次数：72 相关文章
[PDF] academia.edu

[PDF][PDF] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI… - ANTICANCER …, 2010 - academia.edu
Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …
[PDF] psu.edu

[PDF][PDF] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI, PW SYLVESTER - ANTICANCER RESEARCH, 2010 - Citeseer
Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …

Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses stat and Akt signaling in murine mammary tumor cells.

SV Bachawal, VB Wali, PW Sylvester - 2010 - cabidigitallibrary.org
Abstract Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …

Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.

SV Bachawal, VB Wali, PW Sylvester - Anticancer Research, 2010 - europepmc.org
Background Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …
[PDF] researchgate.net

[PDF][PDF] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI… - ANTICANCER …, 2010 - researchgate.net
Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …

[引用][C] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI… - Anticancer …, 2010 - pascal-francis.inist.fr
Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt
Signaling in Murine Mammary Tumor Cells CNRS Inist Pascal-Francis CNRS Pascal and …

Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells

SV Bachawal, VB Wali… - Anticancer research, 2010 - pubmed.ncbi.nlm.nih.gov
Background Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …
[PDF] iiarjournals.org

[PDF][PDF] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI… - ANTICANCER …, 2010 - ar.iiarjournals.org
Background: Heterodimer cooperation between ErbB receptors has limited clinical
usefulness of receptor tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib in the treatment …

[引用][C] Combined γ-Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells

SV BACHAWAL, VB WALI… - Anticancer …, 2010 - International Institute of Anticancer …